COMP <GO>
GYRE vs MRK // GROSS PROFIT MARGIN
Gyre Therapeutics Inc. (NASDAQ) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: GYRE 4
— MRK 9
▲ GROSS PROFIT MARGIN LEADER: GYRE
LAST: $4.56 (-28.94%) • MKT CAP: $714.8M
gross-margins
95.40%
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
gross-margins
74.80%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (GYRE VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | GYRE | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | 95.40% | 74.80% | +20.60 | GYRE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 25.40% | 20.70% | +4.70 | GYRE | /roic <GO> |
| EV/EBITDA & P/E Valuation | 53.3x | 15.3x | +38.00 | MRK | /valuation <GO> |
| Free Cash Flow Yield | -0.03% | 3.42% | -3.45 | MRK | /fcf-yield <GO> |
| Operating Margin | 9.90% | 34.30% | -24.40 | MRK | /operating-margins <GO> |
| Net Profit Margin | 8.50% | 28.10% | -19.60 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 10.20% | 1.30% | +8.90 | GYRE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 14.33 | 5.19 | +9.14 | GYRE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | MRK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 49.8 | 51.7 | -1.90 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 67.2x | 18.4x | +48.80 | MRK | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $714.8M | $361.02B | -$360.31B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | GYRE REV | MRK REV | GYRE GROSS % | MRK GROSS % | GYRE FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $116.6M | $65.01B | 95.4% | 74.8% | -$180.0K | $12.36B |
| FY 2024 | $105.8M | $64.17B | 96.3% | 76.3% | -$6.0M | $18.10B |
| FY 2023 | $113.5M | $60.12B | — | — | $25.9M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
GYRE // BETA —
MRK // BETA 0.92